🚀 VC round data is live in beta, check it out!
Tianjin Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Tianjin Pharma and similar public comparables like Hualan Biological Engineering, Viking Therapeutics, Livzon Pharmaceutical Group, Shijiazhuang Yiling and more.
Tianjin Pharma Overview
About Tianjin Pharma
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.
Founded
1992
HQ
Employees
5.5K
Website
Sectors
Financials (FY)
EV
$4B
Tianjin Pharma Financials
Tianjin Pharma reported last fiscal year revenue of $721M and EBITDA of $383M.
In the same fiscal year, Tianjin Pharma generated $534M in gross profit, $383M in EBITDA, and $312M in net income.
Revenue (LTM)
Tianjin Pharma P&L
In the most recent fiscal year, Tianjin Pharma reported revenue of $721M and EBITDA of $383M.
Tianjin Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $721M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $534M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 74% | XXX | XXX | XXX |
| EBITDA | — | XXX | $383M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 53% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 20% | XXX | XXX | XXX |
| Net Profit | — | XXX | $312M | XXX | XXX | XXX |
| Net Margin | — | XXX | 43% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Tianjin Pharma Stock Performance
Tianjin Pharma has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Tianjin Pharma's stock price is $5.26.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | -1.2% | XXX | XXX | XXX | $0.41 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTianjin Pharma Valuation Multiples
Tianjin Pharma trades at 5.4x EV/Revenue multiple, and 10.2x EV/EBITDA.
EV / Revenue (LTM)
Tianjin Pharma Financial Valuation Multiples
As of April 18, 2026, Tianjin Pharma has market cap of $4B and EV of $4B.
Equity research analysts estimate Tianjin Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tianjin Pharma has a P/E ratio of 13.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 10.2x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 27.5x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 7.3x | XXX | XXX | XXX |
| P/E | — | XXX | 13.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 78.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tianjin Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Tianjin Pharma Margins & Growth Rates
Tianjin Pharma's revenue in the last fiscal year declined by (33%).
Tianjin Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Tianjin Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (33%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 53% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (5%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 54% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Tianjin Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Tianjin Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Hualan Biological Engineering | XXX | XXX | XXX | XXX | XXX | XXX |
| Viking Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Livzon Pharmaceutical Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Shijiazhuang Yiling | XXX | XXX | XXX | XXX | XXX | XXX |
| Ipca Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tianjin Pharma M&A Activity
Tianjin Pharma acquired XXX companies to date.
Last acquisition by Tianjin Pharma was on XXXXXXXX, XXXXX. Tianjin Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Tianjin Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTianjin Pharma Investment Activity
Tianjin Pharma invested in XXX companies to date.
Tianjin Pharma made its latest investment on XXXXXXXX, XXXXX. Tianjin Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Tianjin Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tianjin Pharma
| When was Tianjin Pharma founded? | Tianjin Pharma was founded in 1992. |
| Where is Tianjin Pharma headquartered? | Tianjin Pharma is headquartered in China. |
| How many employees does Tianjin Pharma have? | As of today, Tianjin Pharma has over 5K employees. |
| Is Tianjin Pharma publicly listed? | Yes, Tianjin Pharma is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Tianjin Pharma? | Tianjin Pharma trades under 600329 ticker. |
| When did Tianjin Pharma go public? | Tianjin Pharma went public in 2001. |
| Who are competitors of Tianjin Pharma? | Tianjin Pharma main competitors are Hualan Biological Engineering, Viking Therapeutics, Livzon Pharmaceutical Group, Shijiazhuang Yiling. |
| What is the current market cap of Tianjin Pharma? | Tianjin Pharma's current market cap is $4B. |
| What is the current revenue of Tianjin Pharma? | Tianjin Pharma's last fiscal year revenue is $721M. |
| What is the current EV/Revenue multiple of Tianjin Pharma? | Current revenue multiple of Tianjin Pharma is 5.4x. |
| Is Tianjin Pharma profitable? | No, Tianjin Pharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.